Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Pediatric Clinical Trials Often Discontinued Before Completion, Says Study

XTALKS VITALS NEWS

Pediatric Clinical Trials

As many drugs and medical devices used by children have never been formally tested for safety and efficacy in that population, the recent research highlights the importance of properly-coordinated pediatric clinical trials.

Tweetables from this article:

Tweet: Of 559 pediatric #clinicaltrials, 19% were discontinued in advance of the predetermined study end date http://ctt.ec/N3Wee+Of 559 pediatric clinical trials, 19% were discontinued in advance of the predetermined study end date.

Tweet: 30% of 455 completed #clinicaltrials did not publish results in a scientific journal within a 5-year period http://ctt.ec/AHa4D+30% of 455 completed clinical trials did not publish results in a scientific journal within a 5-year period.

Share this!

August 8, 2016 | by Sarah Massey, M.Sc.

Despite an increased push by federal regulators to encourage sponsors to conduct more pediatric clinical trials, a new study published in the journal, Pediatrics, suggests that many of these clinical trials are abandoned before they’re completed and study data is left unpublished. As many drugs and medical devices used by children have never been formally tested for safety and efficacy in that population, the recent research highlights the importance of properly-coordinated pediatric clinical trials.

“No matter what the focus of the trial, there is some inherent risk for any child to be involved in a trial,” said Dr. Natalie Pica, a resident at Boston Children’s Hospital and co-author on the study, in an interview with Forbes. “We owe it to those participants to conduct those trials ethically and disseminate that information.”

Researchers have long criticized those conducting clinical trials using adult patients for failing to publish study data, however this issue has not been as well studied in trials involving children. To investigate this trend, Pica and her colleague Dr. Florence Bourgeois, an associate physician at Boston Children’s and assistant professor of pediatrics and emergency medicine at Harvard Medical School, analyzed study data available on ClinicalTrials.gov.

In looking at 559 randomized, controlled pediatric clinical trials conducted between 2008 and 2010, the researchers found that 19 percent were discontinued in advance of the predetermined study end date. These 104 clinical trials enrolled a total of 8,369 pediatric volunteers.

Interestingly, Pica and Bourgeois found that patient recruitment problems were to blame for many of these clinical trial stoppages. While funding issues were the least common reason for discontinued studies, academic trials were more likely to be affected by financing troubles compared to those conducted by industry sponsors.

Thirty percent of the 455 completed clinical trials did not publish their results in a scientific journal within a five-year period after the trial ended. According to Pica and Bourgeois, these unpublished trials involved 69,165 pediatric participants.

While the US Food and Drug Administration (FDA) requires most sponsors to register their trials and post the results on ClinicalTrials.gov, many fail to comply with this regulation. Of the 136 clinical trials that did not publish results in scientific journals, only 42 uploaded their data to ClinicalTrials.gov.

The researchers also found that industry-funded pediatric clinical trials were two times more likely to go unpublished years after the trial was completed, compared to academic studies. Pica and Bourgeois point to both the ethical and financial implications of the discontinuation of pediatric clinical trials, and ask whether something should be done to prevent these inefficiencies.

“There has to be some sort of oversight, whether they’re funded by industry or academia, and have feasible goals and available resources to achieve those proposed goals,” said Pica. In Europe, the European Medicines Agency (EMA) is working towards just this kind of increased transparency by releasing new regulations on the availability of clinical trials data.


Keywords: Clinical Trials, Study Sponsors, Pediatrics


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News


Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News


Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


Natural History vs. Registry Studies in Rare Disease


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act


Copyright © 2016-2017 Honeycomb Worldwide Inc.